MediWound Ltd. (MDWD)

Market Cap	59.45M
Revenue (ttm)	20.93M
Net Income (ttm)	-15.45M
Shares Out	40.72M
EPS (ttm)	-0.52
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	136,444
Open	1.44
Previous Close	1.39
Day's Range	1.33 - 1.52
52-Week Range	1.21 - 4.01
Beta	0.96
Analysts	Buy
Price Target	6.46 (+342.5%)
Earnings Date	Nov 14, 2022

About MDWD

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the trea...

• Industry: Pharmaceuticals
• IPO Date: Mar 20, 2014
• CEO: Sharon Malka
• Employees: 77
• Stock Exchange: NASDAQ
• Ticker Symbol: MDWD

Full Company Profile

Financial Performance

In 2021, MediWound's revenue was $23.76 million, an increase of 9.19% compared to the previous year's $21.76 million. Losses were -$13.55 million, 47.4% more than in 2020.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for MDWD stock is "Buy." The 12-month stock price forecast is 6.46, which is an increase of 342.47% from the latest price.

Price Target

$6.46

(342.47% upside)

Analyst Consensus: Buy

Stock Forecasts